Recs

0

Bayer-Teva Animal Deal Clears FTC

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Bayer (NASDAQOTH: BAYRY  ) can close the acquisition of Teva Pharmaceuticals' (NYSE: TEVA  ) U.S. animal health business after receiving the necessary regulatory approval from the Federal Trade Commission, and meeting all the conditions set forth in the initial agreement.

The announcement isn't insignificant, considering that deals for animal health products have run into antitrust issues in recent years. Pfizer (NYSE: PFE  ) had to sell off some of its assets to satisfy regulators when it acquired Wyeth. And Merck (NYSE: MRK  ) and Sanofi (NYSE: SNY  ) eventually gave up the idea of reuniting their animal health businesses, reportedly because of the same issue.

The companies announced the deal last September . Bayer will pay Teva $60 million upfront plus up to $85 million in milestone payments linked to the successful and timely achievement of manufacturing and sales targets.

Bayer will receive a broad range of products for companion animals, including dermatology products, nutraceuticals, anti-infectives, parasiticides, anti-inflammatory brands, and reproductive hormones. In addition to the products, Bayer will take control of a manufacturing site in St. Joseph, Missouri, and nearly 300 employees.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2178362, ~/Articles/ArticleHandler.aspx, 3/4/2015 11:57:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli
TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 18,105.73 -97.64 -0.54%
S&P 500 2,097.83 -9.95 -0.47%
NASD 4,966.31 -13.59 -0.27%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/4/2015 11:41 AM
TEVA $56.40 Down -0.06 -0.11%
Teva Pharmaceutica… CAPS Rating: *****
MRK $58.28 Down -0.06 -0.10%
Merck & Co., Inc. CAPS Rating: ***
PFE $34.72 Up +0.16 +0.46%
Pfizer CAPS Rating: ****
SNY $48.23 Up +0.15 +0.30%
Sanofi (ADR) CAPS Rating: *****

Advertisement